ClinicalTrials.gg
RecruitingNCT07230106Updated Mar 3, 2026

A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer

A Phase 2 interventional study of HS-20093 for Injection and SHR3680 Tablet in Prostate Cancer, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Recruiting at 2 sites in China. Open to male participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-03-03.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
218
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 31 studies in Prostatic Neoplasms by Jiangsu HengRui Medicine Co., Ltd. — 14 open to participants now, 17 under way, 4 of them phase 3. Prostatic Neoplasms · Jiangsu HengRui Medicine Co., Ltd..

Planned enrollment
7th of 31
218 · median 69
Started
2025
with 5 others
Phase 2
5 of 31
1 open now
Primary completion
2028-12
later than 16 of 16 live
Registered
26th of 31
by date

Among the 31 studies in Prostatic Neoplasms by Jiangsu HengRui Medicine Co., Ltd., this one is the 7th largest by planned enrollment, is one of 6 that started in 2025, is one of 5 in phase 2, reaches primary completion later than 16 of the 16 other live ones, and was the 26th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

14 of the 31 studies in Prostatic Neoplasms by Jiangsu HengRui Medicine Co., Ltd. are open now, in 2 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 14 open studies →

Who these studies take

Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years to 80 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Prostatic Neoplasms by Jiangsu HengRui Medicine Co., Ltd., or all of them as a file.
02

Study summary

This is a phase II, multicentre clinical study investigating HS-20093 or SHR2554 in combination with a Novel Hormonal Agent (NHA) for advanced prostate cancer. The trial comprises two cohorts.

03

Conditions studied

  • Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily participate in this clinical study, understand the research procedures, and are able to provide written .
  2. Aged 18 to 80 years (inclusive), male.
  3. performance status of 0 or 1.
  4. Expected survival time ≥12 weeks.
  5. or cytologically confirmed prostate adenocarcinoma, with no features of neuroendocrine carcinoma or small cell carcinoma.
  6. Able to provide sufficient tumor tissue samples for retrospective genetic testing.
  7. Ongoing Androgen Deprivation Therapy (ADT) throughout the study period, i.e., continuous treatment with a GnRH agonist or antagonist (chemical castration) or prior bilateral orchiectomy (surgical castration).
  8. PSA level ≥1 ng/ml at screening.
  9. Adequate organ function levels at baseline assessment.
  10. Male participants with female partners of must agree to refrain from sperm donation and use effective from the time of signing the informed consent form until 4.5 months after the last dose of HS-20093 or 3 months after the last dose of other study treatments, whichever is later.

Exclusion criteria

Exclusion Criteria:

  1. Known or intolerance to the drug(s) or their .
  2. Adverse events from prior anti-tumor therapy have not recovered to Grade ≤1 as per v5.0.
  3. Administration of estrogen, progesterone, or 5-alpha reductase inhibitors within 28 days prior to enrollment.
  4. Administration of herbal medicines known to have anti-prostate cancer or PSA-lowering effects within 14 days prior to enrollment.
  5. Major surgery within 28 days prior to enrollment; palliative radiotherapy within 14 days prior to enrollment; or traumatic minor surgery within 7 days prior to enrollment.
  6. Pathological fractures in critical locations, spinal cord compression, etc., within the recent 6 months.
  7. Non-healing wounds, untreated fractures, or severe bone damage due to disease.
  8. Poorly controlled tumor-related pain.
  9. Dysphagia or other conditions significantly affecting drug absorption.
  10. Known central nervous system metastases or primary brain tumors.
  11. Significant pericardial, pleural, or peritoneal effusion requiring intervention.
  12. Severe cardiovascular or cerebrovascular diseases.
  13. Moderate to severe pulmonary disease significantly affecting respiratory function.
  14. Poorly controlled diabetes.
  15. Serious active infections within 14 days prior to enrollment.
  16. Active , , , or immunodeficiency diseases.
  17. History of other within 5 years prior to enrollment.
  18. Any other condition deemed by the investigator to potentially affect the study.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
218 participants (estimated)

Study arms

  • Experimental
    Cohort 1 Group

    Drug: HS-20093 for Injection · Drug: SHR3680 Tablet · Drug: Abiraterone Tablet

  • Experimental
    Cohort 2 Group

    Drug: SHR3680 Tablet · Drug: SHR2554 Tablet · Drug: Enzalutamide Tablet · Drug: Darotamine Capsule

Interventions

06

What researchers measure

Primary outcomes

  1. Cohort 1: 6-month undetectable Prostate Specific Antigen (PSA) rate.

    Time frame: 6 months.

  2. Cohort 2: Prostate Specific Antigen (PSA) response rate.

    Time frame: About 2 years.

  3. Cohort 2: Adverse events (AEs).

    Time frame: About 2 years.

  4. Cohort 2: Dose-limiting toxicity (DLT).

    Time frame: About 28 days.

Secondary outcomes

  1. Radiographic Progression-Free Survival (rPFS).

    Time frame: About 2 years.

  2. Time to Prostate Specific Antigen (PSA) progression.

    Time frame: About 2 years.

  3. Time to Next Symptomatic Skeletal Event (SSE).

    Time frame: About 2 years.

  4. Time to Next Antineoplastic Therapy (TTNT).

    Time frame: About 2 years.

  5. Objective response rate (ORR).

    Time frame: About 2 years.

  6. Cohort 1: Adverse events (AEs).

    Time frame: About 2 years.

  7. Disease control rate (DCR).

    Time frame: About 2 years.

  8. Duration of response (DoR).

    Time frame: About 2 years.

  9. Overall Survival (OS).

    Time frame: About 2 years.

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Dec 2028, 36 months after the start.

Of 114 industry-sponsored phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 45. This study's planned 36 months is close to that.

Counting every sponsor, half of 724 studies reached it within 53 months; a quarter within 34 and three quarters within 81.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2025
First posted
Nov 17, 2025
StartActual
Dec 8, 2025
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2029
Last update
Mar 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07230106
Responsible party
Sponsor
First posted
Nov 17, 2025
Start date
Dec 8, 2025
Primary completion
Dec 2028 (estimated)
Completion
Dec 2029 (estimated)
Last update
Mar 3, 2026

Study contacts

Wenliang Wang
Contact
wenliang.wang@hengrui.com
+86-0518-82342973
Qi Zhang
Contact
qi.zhang@hengrui.com
+86-021-60453139

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Risvutatug rezetecan · Zeprumetostat

Start the discussion